MK-2870-009
Sacituzumab Tirumotecan Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor -Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
Active, Not Recruiting
Trial purpose
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs).
The primary hypotheses of this study is that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to overall survival (OS).
View full trial information on Clinicaltrials.govNATIONAL TRIAL REFERENCE NUMBER
NCT06305754
When you talk with your doctor or clinical trial team member, please have the national trial reference number available.
Eligibility
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Non-small Cell Lung Cancer
Age Range
18+
Sex
Male/Female
Study Details
Current trial Phase
Phase 3
Tests the medicine or vaccine in approximately 1,000 to 5,000 participants. For medicines, participants have the disease or condition the medicine is designed to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Trial start and end dates
- Trial start date 06-11-2024
- Estimated primary completion date 08-17-2028
- Estimated trial completion date 06-14-2030
Trial Locations
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.